AU2023206175B2 — Treatment of fabry disease in ert-naïve and ert-experienced patients
Assigned to Amicus Therapeutics Inc · Expires 2025-05-22 · 1y expired
What this patent protects
Provided are dosing regimens for the treatment of Fabry disease in a patient. Certain methods relate to the treatment of ERT-experienced Fabry disease patients. Certain methods comprise administering to the patient about 123 mg freebase equivalent of migalastat for improving le…
USPTO Abstract
Provided are dosing regimens for the treatment of Fabry disease in a patient. Certain methods relate to the treatment of ERT-experienced Fabry disease patients. Certain methods comprise administering to the patient about 123 mg freebase equivalent of migalastat for improving left-ventricular mass.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.